Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Elite Pharmaceuticals ( (ELTP) ) has shared an update.
Elite Pharmaceuticals reported a decrease in consolidated revenues and operating profits for the third quarter of fiscal year 2025, which ended on December 31, 2024. The revenues were $14.4 million, down 8% from the previous year, and operating profits fell by 69% to $1.1 million. These results were impacted by shipment delays due to timing differences during the holiday period. A conference call is scheduled to discuss these results and recent business developments.
More about Elite Pharmaceuticals
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. They specialize in oral, controlled-release drug products and operate a cGMP and DEA-registered facility in Northvale, NJ.
YTD Price Performance: -0.55%
Average Trading Volume: 1,491,387
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $585.2M
For an in-depth examination of ELTP stock, go to TipRanks’ Stock Analysis page.
